Julian Theuriet,Marion Masingue,Anthony Behin,Ana Ferreiro,Guillaume Bassez,Pauline Jaubert,Oriana Tarabay,Frédéric Fer,Antoine Pegat,Françoise Bouhour,Juliette Svahn,Philippe Petiot,Laurentiu Jomir,Guy Chauplannaz,Catherine Cornut-Chauvinc,Véronique Manel,Emmanuelle Salort-Campana,Shahram Attarian,Etienne Fortanier,Annie Verschueren,Ludivine Kouton,Jean-Philippe Camdessanché,Céline Tard,Armelle Magot,Yann Péréon,Jean-Baptiste Noury,Marie-Christine Minot-Myhie,Maud Perie,Frederic Taithe,Yacine Farhat,Anne-Laure Millet,Pascal Cintas,Guilhem Solé,Marco Spinazzi,Florence Esselin,Dimitri Renard,Sabrina Sacconi,Andra Ezaru,Edoardo Malfatti,Martial Mallaret,Laurent Magy,Eva Diab,Philippe Merle,Maud Michaud,Maxime Fournier,Aleksandra Nadaj Pakleza,Jean-Baptiste Chanson,Claire Lefeuvre,Pascal Laforet,Pascale Richard,Damien Sternberg,Rocio-Nur Villar-Quiles,Tanya Stojkovic,Bruno Eymard

Abstract:Congenital myasthenic syndromes (CMS) are clinically and genetically heterogeneous diseases caused by mutations affecting neuromuscular transmission. Even if the first symptoms mainly occur during childhood, adult neurologists must confront this challenging diagnosis and manage these patients throughout their adulthood. However, long-term follow-up data from large cohorts of CMS patients are lacking and the long-term prognosis of these patients is largely unknown. We report the clinical features, diagnostic difficulties, and long-term prognosis of a French nationwide cohort of 235 adult patients with genetically confirmed CMS followed in 23 specialized neuromuscular centres. Data were retrospectively analysed. Of the 235 patients, 123 were female (52.3%). The diagnosis was made in adulthood in 139 patients, 110 of whom presented their first symptoms before the age of 18. Mean follow-up time between first symptoms and last visit was 34 years (SD = 15.1). Pathogenic variants were found in 19 disease-related genes. CHRNE -low expressor variants were the most common (23.8%), followed by variants in DOK7 (18.7%) and RAPSN (14%). Genotypes were clustered into four groups according to the initial presentation: ocular group ( CHRNE -LE, CHRND , FCCMS), distal group (SCCMS), limb-girdle group ( RAPSN , COLQ , DOK7 , GMPPB , GFPT1 ), and a variable-phenotype group ( MUSK , AGRN ). The phenotypical features of CMS did not change throughout life. Only four genotypes had a proportion of patients requiring intensive care unit (ICU) admission that exceeded 20%: RAPSN (54.8%), MUSK (50%), DOK7 (38.6%) and AGRN (25.0%). In RAPSN and MUSK patients most ICU admissions occurred before age 18 years and in DOK7 and AGRN patients at or after 18 years of age. Different patterns of disease course (stability, improvement and progressive worsening) may succeed one another in the same patient throughout life, particularly in AGRN, DOK7 and COLQ. At the last visit, 55% of SCCMS and 36.3% of DOK7 patients required ventilation; 36.3% of DOK7 patients, 25% of GMPPB patients and 20% of GFPT1 patients were wheelchair-bound; most of the patients who were both wheelchair-bound and ventilated were DOK7 patients. Six patients died in this cohort. The positive impact of therapy was striking, even in severely affected patients. In conclusion, even if motor and/or respiratory deterioration could occur in patients with initially moderate disease, particularly in DOK7 , SCCMS and GFPT1 patients, the long-term prognosis for most CMS patients was favourable, with neither ventilation nor wheelchair needed at last visit. CHRNE patients did not worsen during adulthood and RAPSN patients, often severely affected in early childhood, subsequently improved.

Current understanding of congenital myasthenic syndromes

Current status of the congenital myasthenic syndromes

Further observations in congenital myasthenic syndromes

Clinical and Pathologic Features of Congenital Myasthenic Syndromes Caused by 35 Genes-A Comprehensive Review

Congenital myasthenic syndromes: increasingly complex

Novel chloride channel gene mutations in two unrelated Chinese families with myotonia congenita.

Congenital myasthenic syndromes

Clinical and genetic characterisation of a large Indian congenital myasthenic syndrome cohort

Molecular Analysis of a Congenital Myasthenic Syndrome Due to a Pathogenic Variant Affecting the C-Terminus of ColQ

Diagnostic yield of a practical electrodiagnostic protocol discriminating between different congenital myasthenic syndromes

Modulation of the Acetylcholine Receptor Clustering Pathway Improves Neuromuscular Junction Structure and Muscle Strength in a Mouse Model of Congenital Myasthenic Syndrome

Congenital Myasthenic Syndromes: a Clinical and Treatment Approach

Abnormal decrement on high-frequency repetitive nerve stimulation in congenital myasthenic syndrome with GFPT1 mutations and review of literature

Mechanisms of Congenital Myasthenia Caused by Three Mutations in the COLQ Gene

A spontaneous missense mutation in the chromodomain helicase DNA-binding protein 8 (CHD8) gene: a novel association with congenital myasthenic syndrome

Congenital myasthenic syndromes due to heteroallelic nonsense/missense mutations in the acetylcholine receptor epsilon subunit gene: identification and functional characterization of six new mutations

Congenital myasthenic syndromes in adults: clinical features, diagnosis and long-term prognosis

Clinical features of the myasthenic syndrome arising from mutations in GMPPB

Congenital myopathies: pathophysiological mechanisms and promising therapies

Characterization of Clinical Phenotypes in Congenital Myasthenic Syndrome Associated with the c.1327delG Frameshift Mutation in CHRNE Encoding the Acetylcholine Receptor Epsilon Subunit

Congenital myasthenia syndrome in a Chinese family with mutations in MUSK: A hotspot mutation and literature review.